Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD

24.55  -0.1 (-0.41%)

After market: 24.55 0 (0%)

Fundamental Rating

3

Taking everything into account, GPCR scores 3 out of 10 in our fundamental rating. GPCR was compared to 198 industry peers in the Pharmaceuticals industry. While GPCR has a great health rating, there are worries on its profitability. GPCR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GPCR had negative earnings in the past year.
In the past year GPCR has reported a negative cash flow from operations.
GPCR had negative earnings in each of the past 5 years.
GPCR had a negative operating cash flow in each of the past 5 years.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of GPCR (-13.56%) is better than 67.68% of its industry peers.
GPCR has a Return On Equity of -14.17%. This is in the better half of the industry: GPCR outperforms 74.75% of its industry peers.
Industry RankSector Rank
ROA -13.56%
ROE -14.17%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for GPCR has been increased compared to 1 year ago.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

GPCR has an Altman-Z score of 22.16. This indicates that GPCR is financially healthy and has little risk of bankruptcy at the moment.
GPCR's Altman-Z score of 22.16 is amongst the best of the industry. GPCR outperforms 92.42% of its industry peers.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.16
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

GPCR has a Current Ratio of 24.74. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
GPCR's Current ratio of 24.74 is amongst the best of the industry. GPCR outperforms 94.95% of its industry peers.
GPCR has a Quick Ratio of 24.74. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 24.74, GPCR belongs to the best of the industry, outperforming 94.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.74
Quick Ratio 24.74
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GPCR have decreased strongly by -10.14% in the last year.
EPS 1Y (TTM)-10.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-326.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.33%
EPS Next 2Y4.8%
EPS Next 3Y0.35%
EPS Next 5Y22.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GPCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GPCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.8%
EPS Next 3Y0.35%

More info and screens

0

5. Dividend

5.1 Amount

GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (5/23/2025, 8:20:01 PM)

After market: 24.55 0 (0%)

24.55

-0.1 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners108.85%
Inst Owner Change-6.95%
Ins Owners2.46%
Ins Owner Change24.94%
Market Cap1.41B
Analysts86.32
Price Target80.29 (227.05%)
Short Float %51.78%
Short Ratio9.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-209.36%
Min EPS beat(2)-216.46%
Max EPS beat(2)-202.27%
EPS beat(4)2
Avg EPS beat(4)-96.22%
Min EPS beat(4)-216.46%
Max EPS beat(4)22.26%
EPS beat(8)3
Avg EPS beat(8)-97.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.8%
PT rev (3m)-6.85%
EPS NQ rev (1m)0.59%
EPS NQ rev (3m)2.18%
EPS NY rev (1m)-22.31%
EPS NY rev (3m)-64.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS0
BVpS15.03
TBVpS15.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.56%
ROE -14.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 130.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.74
Quick Ratio 24.74
Altman-Z 22.16
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-326.32%
EPS Next Y19.33%
EPS Next 2Y4.8%
EPS Next 3Y0.35%
EPS Next 5Y22.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.52%
EBIT Next 3Y-27.41%
EBIT Next 5Y0.25%
FCF growth 1Y-44.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.73%
OCF growth 3YN/A
OCF growth 5YN/A